Annals
Established in 1927 by the American College of Physicians
:
Advanced search
 
box Article
 arrow  Table of Contents                
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Moulding, T.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space

LETTER

Monitored Isoniazid Prophylaxis for Low-Risk Tuberculin Reactors

right arrow Tom Moulding, MD

15 June 1998 | Volume 128 Issue 12 Part 1 | Page 1048


TO THE EDITOR:

Decision analyses should be helpful in selecting indications for isoniazid prophylaxis. In reality, however, they are not helpful because they use widely different assumptions that lead to vastly different conclusions. This is demonstrated by the contrasting analyses by Salpeter and colleagues [1], which concluded that isoniazid given to all tuberculin rectors would result in significant savings and large health benefits, and Tsevat and colleagues [2], which concluded that isoniazid reduces life expectancy.

Salpeter and associates assumed that the annual rate of the development of tuberculosis would be a constant 0.0006 cases per year, starting with the 15th year after the results of a tuberculin test were known. In contrast, Tsevat and coworkers assumed that the rates would decrease with the passage of time, an assumption reinforced by Chiba's study [3]. The latter showed a threefold decrease in rates between the 20th and 30th years.

Salpeter and coworkers assumed lifetime protection of 85% after 6 months of isoniazid therapy, whereas the study they cited showed only 65% protection with 6 months of isoniazid therapy for the 5 years that were studied [4]. Furthermore, the rates in the placebo group approached the rates in the isoniazid group in the fifth year, suggesting minimal protection thereafter.

The fatal isoniazid-related hepatitis rate of 0.00001 to 0.00002 deaths per isoniazid recipient assumed by Salpeter and colleagues is probably low because of serious underreporting of isoniazid-related deaths. Salpeter and coworkers used age-specific tuberculosis case-fatality rates that were higher and more realistic than the rates used by Tsevat and colleagues but did not mention the health concern factor. The latter probably reduces the tuberculosis case-fatality rate and cost of treating tuberculosis in persons concerned enough to take self-administered preventive treatment [5].

If decision analyses for isoniazid prophylaxis are to be useful, they must be repeated after the assumptions are refined by careful study and discussion among knowledgeable parties.


Author and Article Information
space
up arrowTop
dotAuthor & Article Info
down arrowReferences

Harbor-UCLA Medical Center; Torrance, CA 90502


References
space
up arrowTop
up arrowAuthor & Article Info
dotReferences

1. Salpeter SR, Sanders GD, Salpeter EE, Owens DK. Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: a risk–benefit and cost-effectiveness analysis. Ann Intern Med. 1997; 127:1051-61.

2. Tsevat J, Taylor WC, Wong JB, Pauker SG. Isoniazid for the tuberculin reactor: take it or leave it. Am Rev Respir Dis. 1988; 137:215-20.

3. Chiba Y. Significance of endogenous reactivation: 30 year follow up of tuberculin convertors. Bulletin of International Union Against Tuberculosis. 1974; 49:321-4.

4. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis-Committee on Prophylaxis. Bull WHO. 1982; 60:555-64.

5. Moulding T, Barnes P. Isoniazid for the tuberculin reactor: take it or leave it [Letter]. Am Rev Respir Dis. 1988; 138:489.

About Letters
space

The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:

•Include no more than 300 words of text, three authors, and five references

•Type with double-spacing

•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.

Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.

Annals welcomes electronically submitted letters.





box Article
 arrow  Table of Contents                
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Moulding, T.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space


 Home | Current Issue | Past Issues | In the Clinic | ACP Journal Club | CME | Collections | Audio/Video | Mobile | Subscribe | Tools | Help | ACP Online